Published On: Wed, Oct 19th, 2016

Broker Changes For Insys Therapeutics, Inc. (INSY)


Recently stock market analysts have updated their consensus ratings on shares of Insys Therapeutics, Inc. (INSY).

Most recent broker ratings

10/10/2016 – Insys Therapeutics, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 18 price target on the stock.

09/22/2016 – Insys Therapeutics, Inc. had its “outperform” rating reiterated by analysts at RBC Capital. They now have a USD 26 price target on the stock.

08/24/2016 – Insys Therapeutics, Inc. had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 28 price target on the stock.

04/13/2016 – Janney Montgomery Scott began new coverage on Insys Therapeutics, Inc. giving the company a “buy” rating. They now have a USD 22 price target on the stock.

08/10/2015 – Insys Therapeutics, Inc. had its “market perform” rating reiterated by analysts at Oppenheimer.

05/15/2015 – Insys Therapeutics, Inc. was upgraded to “strong-buy” by analysts at Zacks. They now have a USD 68 price target on the stock.

03/05/2014 – Insys Therapeutics, Inc. had its “outperform” rating reiterated by analysts at JMP Securities. They now have a USD 99 price target on the stock.

03/05/2014 – Insys Therapeutics, Inc. was upgraded to “overweight” by analysts at EVA Dimensions.

Insys Therapeutics, Inc. has a 50 day moving average of 13.11 and a 200 day moving average of 14.63. The stock’s market capitalization is 806.16M, it has a 52-week low of 10.59 and a 52-week high of 33.88.

The share price of the company (INSY) was up +3.49% during the last trading session, with a high of 11.79 and the volume of Insys Therapeutics, Inc. shares traded was 1089946.

Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company’s lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.